| People | Locations | Statistics |
|---|---|---|
| Naji, M. |
| |
| Motta, Antonella |
| |
| Aletan, Dirar |
| |
| Mohamed, Tarek |
| |
| Ertürk, Emre |
| |
| Taccardi, Nicola |
| |
| Kononenko, Denys |
| |
| Petrov, R. H. | Madrid |
|
| Alshaaer, Mazen | Brussels |
|
| Bih, L. |
| |
| Casati, R. |
| |
| Muller, Hermance |
| |
| Kočí, Jan | Prague |
|
| Šuljagić, Marija |
| |
| Kalteremidou, Kalliopi-Artemi | Brussels |
|
| Azam, Siraj |
| |
| Ospanova, Alyiya |
| |
| Blanpain, Bart |
| |
| Ali, M. A. |
| |
| Popa, V. |
| |
| Rančić, M. |
| |
| Ollier, Nadège |
| |
| Azevedo, Nuno Monteiro |
| |
| Landes, Michael |
| |
| Rignanese, Gian-Marco |
|
Gil, Lidia
in Cooperation with on an Cooperation-Score of 37%
Topics
Publications (1/1 displayed)
Places of action
| Organizations | Location | People |
|---|
article
BCR::ABL1-like acute lymphoblastic leukaemia: a single institution experience on identification of potentially therapeutic targetable cases
Abstract
<jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p><jats:italic>BCR::ABL1</jats:italic>-like acute lymphoblastic leukaemia (<jats:italic>BCR::ABL1</jats:italic>-like ALL) is characterized by inferior outcomes. Current efforts concentrate on the identification of molecular targets to improve the therapy results. The accessibility to next generation sequencing, a recommended diagnostic method, is limited. We present our experience in the <jats:italic>BCR::ABL1</jats:italic>-like ALL diagnostics, using a simplified algorithm.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Out of 102 B-ALL adult patients admitted to our Department in the years 2008–2022, 71 patients with available genetic material were included. The diagnostic algorithm comprised flow cytometry, fluorescent in-situ hybridization, karyotype analysis and molecular testing with high resolution melt analysis and Sanger Sequencing. We recognized recurring cytogenetic abnormalities in 32 patients. The remaining 39 patients were screened for <jats:italic>BCR::ABL1</jats:italic>-like features. Among them, we identified 6 patients with <jats:italic>BCR::ABL1</jats:italic>-like features (15.4%). Notably, we documented <jats:italic>CRLF2</jats:italic>-rearranged (<jats:italic>CRLF2</jats:italic>-r) <jats:italic>BCR::ABL1</jats:italic>-like ALL occurrence in a patient with long-term remission of previously <jats:italic>CRLF2-</jats:italic>r negative ALL.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>An algorithm implementing widely available techniques enables the identification of <jats:italic>BCR::ABL1</jats:italic>-like ALL cases in settings with limited resources.</jats:p></jats:sec>